Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents

Crown Bioscience, Inc. and ERS Genomics Ltd. have signed a global license agreement for access to the foundational CRISPR/Cas9 patent portfolio held by ERS, which provides the company full license to operate globally using CRISPR/Cas9 for gene editing.
[ERS Genomics Limited]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News